Objectives: The therapeutic effects of botulinum neurotoxin (BoNT) are well documented in upper limb spasticity. However, several factors may influence treatment efficacy, such as injection technique, targeting of neuromuscular junctions (NMJs), and the concentration and volume of injected toxin.
F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y
STRENGTHS AND LIMITATIONS OF THIS STUDY
• This study contributes to the ongoing discussion around the significance of targeted injections in BoNT treatment
• It is a prospective randomized study with a third-party blinded evaluation of a primary endpoint • Unfortunately, recruitment did not achieve the pre-planned study population and this is likely to have prevented statistical demonstration of non-inferiority
• Due to the heterogenic population, a cross-over design might have given a stronger power and been able to show non inferiority
• To our knowledge, this is one of only a few studies that has randomized a larger number of patients in a real clinical situation for evaluating the concept of NMJ targeting
INTRODUCTION
Spasticity is a sensory-motor control disorder, resulting from an upper motor neuron lesion, presenting as intermittent or sustained involuntary activation of muscles. [1] Patients with spasticity may suffer from decreased active movement, increased disability and impaired function. [2] Intramuscular injections with botulinum toxin (BoNT) is a documented efficacious and well tolerated treatment option for these patients, which has an established position in clinical practice. [3 4 ] Studies with abobotulinumtoxinA (aboBoNT-A, Dysport) have demonstrated a beneficial effect on spasticity in terms of decreased resistance to passive movement, improvements in pain and goal attainment as well as in active function. [5] [6] [7] [8] [9] [10] The therapeutic effects of BoNT have been extensively studied in upper limb spasticity, which has been summarized in a number of recent reviews. [11] [12] [13] Several factors can influence treatment efficacy, such as injection technique, targeting of neuromuscular junctions (NMJ), concentration of BoNT and volume of injected solution, as well as The Neuromuscular Junction (NMJ) study was an international, multicenter, prospective, randomized, evaluator-blinded, parallel-group study, comparing two different injection techniques (NCT01682148). Patients were injected with botulinum toxin (abobotulinumtoxinA, Dysport) for the treatment of upper limb spasticity. Patients were randomized to 1 of 2 groups; 1) the Current practice group receiving injections according to current clinical practice (without regard to NMJ) and 2) the NMJ-targeted group receiving injections according to a predefined NMJ targeting technique with lower concentration of the toxin, figure 1.
Patient involvement
In this study, the patient-centric research question was developed with the aim of limiting the injection points and thus limiting burden of injections. Evaluation of outcome measures was via the patient-centric goal attainment scaling (GAS) score where the patient and treating physician agree on a goal that is meaningful for the patient, and evaluate the treatment by goal attainment.
While patient priorities and preferences were considered when developing the study design, this was prior to discussion on patient involvement, hence, no patients were consulted on the design.
Patients were asked whether they would like to participate in the study and decided if they wanted to participate or not after provision of informed consent. When completing the informed consent form, patients could indicate whether they wished to be informed of the study results or not.
Patients wishing to know the results were informed by their investigator.
Patient recruitment
Medical centers in Finland, Denmark, Sweden and Norway (n=39) were included to recruit patients for participation in the study. Approval from the local ethical review board was granted in each separate country. The study conformed to the principles of the Helsinki Declaration and all patients signed an informed consent form ahead of participation.
Inclusion criteria were; age ˃ 18 years, provision of written informed consent and suffering from upper limb spasticity position pattern type 1, 3 or 4 following stroke or traumatic brain injury. [22] The position patterns were based on characteristic arm positions and postures recognized in upper limb spasticity. [23] Spasticity was evaluated according to the Modified Ashworth Scale (MAS), with a baseline score of 2 or 3 points at inclusion. Patients had received at least 2 consecutive previous treatment cycles with BoNT-A, of which at least the latest had to have been with aboBoNT-A with observed good efficacy according to investigator judgment. Furthermore, the investigator should have judged a need for a repeat of the same treatment modality as the previous cycle and the last BoNT-A treatment should have been dated more than 12 weeks before study entry. Subjects were randomized (1:1) to 1 of 2 treatment groups. The patients were stratified according to 3 different arm 
Randomization procedure:
A randomization list was prepared by a statistician independent from the study, and was provided to the eCRF provider who incorporated it into the eCRF. The list was stratified for three arm spasticity position patterns (1, 3 and 4) and for participating countries, and generated with a balanced 1:1 ratio. Once eligibility was confirmed, the Investigator entered eligibility data into the e-CRF. If the patient was eligible, based on the predefined randomization list, the e-CRF system would automatically assign the first not-used randomization number corresponding to the patient's spasticity pattern and country, to get the applicable treatment administration group allocation. The study drug was provided in 3 mL vials containing 300 U of aboBoNT-A and diluted by the investigator to the assigned concentration, 100 U/mL or 300 U/mL according to the assigned treatment group.
Blinding:
This was an open study with respect to study drug. However, the treatment group assigned to a randomization number was to be blinded prior to allocation. To optimize protocol blindness at each site, all study injections were to be performed by one of the investigators (unblinded) and all efficacy assessments were to be performed by another qualified study personnel, blinded to the injection technique. The e-CRF provided two user profiles, one which was able to see the randomization information (treatment arm) and another one for the evaluators, for which the treatment arm was hidden.
Treatments
Optimal dose of aboBoNT-A (abobotulinumtoxinA, Dysport) for each subject was determined by the investigator at the first visit to optimize treatment efficacy prior to inclusion (see patient recruitment). Maximum dose injected in the spastic arm was 800 units. Patients in the current practice group received injections according to current clinical practice (toxin concentration of 300 units/ml). The NMJ-targeted group were injected using an NMJ targeted technique (low toxin concentration of 100 units/ml). All injections were targeted to the same muscles of the arm and performed with support of electromyography (EMG) guiding and/or ultrasound (US). The study F o r p e e r r e v i e w o n l y treatment was performed using the same individual dose as determined at the pre-study treatment visit.
The 2 different injection patterns are outlined in Table 1 below. Each patient visited the clinic on at least 3 occasions. The first visit was devoted to screening, randomization and treatment with aboBoNT-A. The second visit was scheduled 4 weeks after the first injection. Lastly, the third visit was a follow-up at 12 weeks after the first injection. Additional treatment with aboBoNT-A was given if necessary. For the group treated with NMJ-targeted injections, the localization of the single injection was based on previously published descriptions of the motor endplate bands within human arm muscles in relation to external landmarks. [24 25] Assessment of arm spasticity was based on flexion of the elbow joint as well as muscle activity specific to position patterns 1, 3 and 4, as previously described by Hefter et al. [23] 
Assessments and outcome measures
The aim of the study was to assess non-inferiority of a treatment strategy using fewer injections of low concentration BoNT, as compared to current clinical practice. Primary efficacy was measured as change in MAS (scored between 0 and 4); i.e. baseline MAS score in the elbow flexors was compared to MAS score measured 4 weeks post injection. Secondary efficacy endpoints included change in MAS score in the elbow flexors from baseline to Week 12, intensity of spasticity related pain as measured by a Visual Analog Scale (VAS; scored 0-100) at baseline, Week 4 and Week 12, pain from injection measured by a VAS at first visit, score on the GAS (scored from -2 to 2) at Week 4 or Week 12, subject global evaluation of treatment effect at the study end, and investigator preference of injection technique. The statistical analyses were performed in accordance with ICH E9 guideline and were based on the pooled data from the individual study sites, unless otherwise stated. All statistical analyses were performed by PCG using Statistical Analysis System® (SAS version 9.4).
RESULTS

Patient population
The final population size in the two treatment arms did not reach the pre-planned population size of 272 subjects. The main reasons for this were recruitment difficulties and protocol violations. In all, 20
centers included a total of 88 patients who were subsequently randomized in the study (Intention To Treat population). However, only 54 of these completed the study without protocol violation (Per Protocol population). Violation of protocol was recognized for 34 patients. Of these, 23 were not injected as per protocol and 11 had other violations, for example 5 patients had missing MAS (Modifies Ashworth Scale) evaluations. Baseline characteristics for the ITT and PP populations for both aboBoNT-A treatment regimens (Current practice vs. NMJ-targeted) are shown in Table 2 . 
Primary endpoint
The proportion of MAS responders (defined as ≥1 level decrease in MAS from baseline) in the ITT population for elbow flexors at Week 4 post-injection was 72.7% in the group treated as current 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure 2 . There were no significant differences observed between groups.
Non-inferiority was not shown in either population. Mean (SD) changes in MAS score for elbow flexors at Week 4 compared to baseline are presented in Figure 3 .
Secondary endpoints
Secondary endpoints evaluated were: MAS responders at 12 weeks, improvement in GAS score as well as spasticity pain between baseline and 4 weeks and injection related pain at first visit. All secondary endpoints were measured on the ITT population. No secondary endpoint showed any significant difference between the two groups. Results from the secondary endpoints are summarized in Table 3 . the TEAEs reported by more than one subject were urinary tract infection (reported by 4 subjects, 4.5%), headache and epilepsy (both reported by 3 subjects, 3.4%), and pain in extremity, epididymitis and fatigue (all three reported by 2 subjects, 2.3%). Regarding investigator assessed
TEAEs related to treatment, 3 events were reported in 2 subjects in the group treated as current practice (4.5%) and 1 event was reported in the group treated with NMJ-targeted injections (2.3%). In the Current practice group, these concerned 1 patient with injection site hypersensitivity, which was assessed as mild and study treatment related, and 1 patient with dysphagia and fatigue, both of which were assessed as mild and study treatment related. In the NMJ-targeted group, 1 patient experienced fatigue, assessed as moderate and related to the study treatment. Overall, the majority of events reported were mild to moderate in intensity. Additionally, in the NMJ-targeted group, 3 subjects experienced severe TEAEs which were assessed as non-related to aboBoNT-A treatment by the investigator. Two subjects in each group experienced serious adverse events judged by the investigator as non-related to the treatment. There were no reported TEAEs resulting in withdrawal or death.
DISCUSSION
In the current study, both injection techniques using aboBoNT-A resulted in a high proportion of responders, while no statistically significant difference between the injection strategies was observed. However, the number of subjects included in the study was a limiting factor and may
explain the failure to demonstrate non-inferiority statistically. Previously, the injection strategy used for BoNT treatment has been identified as important for optimizing treatment outcomes. [14 26 27] This study contributes to the discussion about the significance of targeted injections.
Assessment of the ability for passive movements, as measured by MAS, did not show any significant differences between the groups, at 4 weeks or at 12 weeks follow-up. Generally, injection techniques based on a lower number of injection points, as in the NMJ strategy, are expected to be preferable for both patients and physicians.
Gracies et al (2009) suggested that high-volume or endplate targeted BoNT injections results in superior neuromuscular blockade, contraction and spasticity reduction than low volume, non-targeted injections. [20] In the Gracies study, the effect was demonstrated using the Tardieu scale in contrast to the MAS used in the current study. Hence, the results are not directly comparable. The lack of statistically significant differences between the strategies in our study might, however, be explained by the different outcome measures used. It might not be possible to The GAS, which is a more sensitive scale than MAS to investigate functionally important changes after injection, [28] generated similar results between the strategies used in our study.
The experienced pain related to spasticity or injection was mild or moderate. A reduction in pain intensity after 4 weeks was observed in both treatment strategies. Pain associated with injections of
BoNT could hypothetically influence optimal treatment results and goal attainment by affecting
compliance. An inverse relationship between injection site pain and compliance to BoNT treatment has, for instance, been reported for hyperhidrosis. [29] The study did not disclose any previously unknown adverse events. Furthermore, there was no difference in the observed frequency of adverse events between the two injection strategies, as assessed in the ITT population.
The major limitation of this study was the low number of included subjects, as compared to the number needed according to the calculation of statistical power conducted before the study. Most likely, this prevented statistical demonstration of non-inferiority. The study compared current clinical practice with a NMJ targeting/higher volume technique. As a result, both the targeted injection as well as increased the increased volume contributes to the effect on the spastic muscle in the NMJ group. Both treatment arms experienced a high response rate to treatment, suggesting that a much larger study population is needed to be able to detect any difference, if present at all.
In summary, the current study provides further insights in the discussions of the effectiveness of
BoNT injections targeted to NMJs. Since this strategy enables patients to be treated using fewer injections, the approach may minimize the potentially painful injection experience while having a similar effect on spasticity. Furthermore, the high number of responders with both injection techniques indeed confirms aboBoNT-A to be an effective treatment option for spasticity. Thus, any measures that could have an effect on implementation and/or compliance are important.
This study was conducted on flexors in the spastic arm, and the effect on other spastic muscles using NMJ targeted injections has yet to be substantiated. Several previous publications suggest injections 
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Data sharing statement
Trial data analyzed during the reported study are available to qualified researchers. Reasonable requests should be directed to the corresponding author. Interventions: Randomization (1:1) to receive a single dose of aboBoNT-A (≤800 units) according to either current clinical practice (300 units/mL) or as an NMJ-targeted injection (100 units/mL).
Primary outcome measure: Proportion of patients with a ≥1-level reduction from baseline in MAS score at Week 4 post-injection (responders).
Results:
In the ITT population, the proportion of responders at elbow flexors was 72.7% in the 
STRENGTHS AND LIMITATIONS OF THIS STUDY  This study contributes to the ongoing discussion around the significance of targeted injections in BoNT treatment
 The study failed to reach its recruitment target, preventing the demonstration of statistically significant non-inferiority  Due to the heterogenic population, a cross-over design might have given a stronger power
and been able to demonstrate non-inferiority  Even though recruitment was terminated early, this study is one of the larger evaluatorblinded prospective randomized studies performed investigating the NMJ targeting treatment technique.
 MAS was used as the primary outcome measure in this study, it is possible that minor changes were not captured by this score, suggesting that future studies should consider using additional methods of evaluations, such as eletromyography blockade, contraction and spasticity reduction than low volume, non-targeted injections. [20] This study explores the hypothesis that the effect of a single high volume aboBoNT-A injection of low concentration per muscle, if targeted to the area of the NMJ zones, is equal to the effect of several injections using standard injection practices. An international randomized, multicenter, evaluatorblinded study was thus performed to evaluate non-inferiority between the two different injection strategies.
MATERIALS AND METHODS
Study design
The Neuromuscular Junction (NMJ) study was an international, multicenter, prospective, randomized, evaluator-blinded, parallel-group study, comparing two different injection techniques 
Patient and public involvement statement
In this study, the patient-centric research question was developed with the aim of limiting the injection points and thus limiting burden of injections. The patient´s experience of the different injection techniques was recorded by measuring injection pain using a Visual Analogue Scale (VAS). Evaluation of outcome measures was via the patient-centric goal attainment scaling (GAS) score where the patient and treating physician agree on a goal that is meaningful for the patient, and evaluate the treatment by goal attainment.
Patients wishing to know the results were informed by their investigator. 
Patient recruitment
Medical centers in
Randomization procedure:
A randomization list was prepared by a statistician independent from the study, and was provided to the eCRF provider who incorporated it into the eCRF. The list was stratified for three arm spasticity position patterns (1, 3 and 4) and for participating countries, and generated with a balanced 1:1 treatment ratio. Once eligibility was confirmed, the Investigator entered eligibility data into the e-CRF. If the patient was eligible, based on the predefined randomization list, the e-CRF system would automatically assign the first not-used randomization number corresponding to the patient's spasticity pattern and country, to get the applicable treatment administration group allocation. The study drug was provided in 3 mL vials containing 300 U of aboBoNT-A and diluted by the investigator to the assigned concentration, 100 U/mL or 300 U/mL according to the assigned treatment group.
Blinding:
Treatments
Optimal dose of aboBoNT-A (abobotulinumtoxinA, Dysport) for each subject was determined by the investigator at the first visit to optimize treatment efficacy prior to inclusion (see patient recruitment). Maximum dose injected in the spastic arm was 800 units. Patients in the current practice group received injections according to current clinical practice (toxin concentration of 300 units/ml). The NMJ-targeted group were injected using an NMJ targeted technique (low toxin concentration of 100 units/ml). All injections were targeted to the same muscles of the arm and performed with support of electromyography (EMG) guiding and/or ultrasound (US). The study treatment was performed using the same individual dose as determined at the pre-study treatment visit.
The 2 different injection patterns are outlined in Table 1 . Each patient visited the clinic on at least 3 occasions. The first visit was devoted to screening, randomization and treatment with aboBoNT-A.
The second visit was scheduled 4 weeks after the first injection. Lastly, the third visit was a follow- 
Assessments and outcome measures
The aim of the study was to assess non-inferiority of a treatment strategy using fewer injections of low concentration BoNT, as compared to current clinical practice. The primary endpoint was percentage of patients with at least a 1 level decrease in MAS (scored between 0 and 4).Baseline MAS score in the elbow flexors was compared to MAS score measured 4 weeks post injection. A ≥1 level decrease in MAS from baseline was considered clinically meaningful [26] . Secondary endpoints included change in MAS score in the elbow flexors from baseline to Week 12, intensity of spasticity related pain as measured by a VAS (; scored 0-100) at baseline, Week 4 and Week 12, pain from injection measured by a VAS at first visit, score on the GAS (scored from -2 to 2) at Week 4 or Week 12, subject global evaluation of treatment effect at the study end, and investigator preference of injection technique.
Sample size and statistics
Statistical methods: both the primary endpoint (MAS responders at Week 4) and the non-inferiority design were taken into account for the sample size calculation. A two-sided 95% confidence interval for the difference in clinical success rates was calculated using a generalized linear model with
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y treatment, spasticity position patterns, country and baseline MAS score as factors. Assuming a responder rate (π) of 63% in the reference group, a sample size of 122 patients per group would provide 80% power to detect a clinically relevant delta (Δ) of 17% at an alpha (α) level of 2.5% (onesided). Assuming a dropout rate of 10%, 136 patients per group were required to be randomized (i.e. 272 patients in total).
The statistical analyses were performed in accordance with ICH E9 guideline and were based on the pooled data from the individual study sites, unless otherwise stated. All statistical analyses were performed by PCG using Statistical Analysis System® (SAS version 9.4).
RESULTS
Patient population
The study was terminated early owing to slow recruitment, meaning the final population size in the two treatment arms did not reach the pre-planned population size of 272 subjects. The main reasons for this were recruitment difficulties and protocol violations. In all, 20 centers included a total of 88 patients who were subsequently randomized in the study (Intention To Treat population). However, only 54 of these completed the study without protocol violation (Per Protocol population) (Supplementary Figure 1) . Violation of protocol was recognized for 34 patients. Of these, 23 were not injected as per protocol and 11 had other violations, for example 5 patients had missing MAS (Modifies Ashworth Scale) evaluations. Baseline characteristics for the ITT and PP populations for both aboBoNT-A treatment regimens (Current practice vs. NMJ-targeted) are shown in Table 2 . 
Secondary endpoints
Secondary endpoints evaluated were: MAS responders at 12 weeks, improvement in GAS score as well as spasticity pain between baseline and 4 weeks and injection related pain at first visit. All secondary endpoints were measured on the ITT population. No secondary endpoint showed any significant difference between the two groups. Results from the secondary endpoints are summarized in 
Safety
The adverse events reported were consistent with the known safety profile of aboBoNT-A and no new adverse effects were observed. Treatment emergent adverse events (TEAEs) were experienced in 11 subjects in the group treated as current practice (25.0%; 16 events were reported) and 15 in the group treated with NMJ-targeted injections (34.1%; 24 events were reported). For all subjects (N=88), the TEAEs reported by more than one subject were urinary tract infection (reported by 4 subjects, 4.5%), headache and epilepsy (both reported by 3 subjects, 3.4%), and pain in extremity, epididymitis and fatigue (all three reported by 2 subjects, 2.3%). Regarding investigator assessed TEAEs related to treatment, 3 events were reported in 2 subjects in the group treated as current practice (4.5%) and 1 event was reported in the group treated with NMJ-targeted injections (2.3%). In the Current practice group, these concerned 1 patient with injection site hypersensitivity, which was assessed as mild and study treatment related, and 1 patient with dysphagia and fatigue, both of which were assessed as F o r p e e r r e v i e w o n l y mild and study treatment related. In the NMJ-targeted group, 1 patient experienced fatigue, assessed as moderate and related to the study treatment. Overall, the majority of events reported were mild to moderate in intensity. Additionally, in the NMJ-targeted group, 3 subjects experienced severe TEAEs which were assessed as non-related to aboBoNT-A treatment by the investigator. Two subjects in each group experienced serious adverse events judged by the investigator as non-related to the treatment. There were no reported TEAEs resulting in withdrawal or death.
DISCUSSION
In the current study, both injection techniques using aboBoNT-A resulted in a high proportion of responders, while no statistically significant difference between the injection strategies was observed.
However, the number of subjects included in the study was a limiting factor and may explain the failure to demonstrate non-inferiority statistically. Previously, the injection strategy used for BoNT treatment has been identified as important for optimizing treatment outcomes. [14 27 28] Indeed, NMJ-targeted strategies have the advantage of requiring fewer injection points, potentially minimizing pain associated with administration, and are expected to be preferable for both patients and physicians. This study contributes to the discussion about the significance of targeted injections.
Gracies et al (2009) suggested that high-volume or endplate targeted BoNT injections results in superior neuromuscular blockade, contraction and spasticity reduction than low volume, nontargeted injections. [20] In the Gracies study, the effect was demonstrated using the Tardieu scale in contrast to the MAS used in the current study. Hence, the results are not directly comparable. The lack of statistically significant differences between the strategies in our study might, however, be explained by the different outcome measures used. It might not be possible to capture a statistical difference with the MAS scale in this limited study group, due to lack of power. The GAS, which is a more sensitive scale than MAS to investigate functionally important changes after injection, [29] generated similar results between the strategies used in our study.
compliance. An inverse relationship between injection site pain and compliance to BoNT treatment has, for instance, been reported for hyperhidrosis.
[30]
The study did not disclose any previously unknown adverse events. Furthermore, there was no difference in the observed frequency of adverse events between the two injection strategies, as The major limitation of this study was the low number of included subjects, as compared to the number needed according to the calculation of statistical power conducted before the study. Most likely, this prevented statistical demonstration of non-inferiority. The main reasons underlying the slow recruitment were difficulties in finding patients who were receiving continuous treatment who also had a MAS score of 2 or higher in the elbow flexors. Also, patients treated successfully with BoNT-A did not fluctuate to the extent that they increased a full level on the MAS between injections. A further limitation was the fact that although patient priorities and preferences were considered when developing the study, patients were not consulted specifically on its design.
However, given the focus of the study, this was unlikely to have had a major impact on the overall findings.
The study compared current clinical practice with a NMJ targeting/higher volume technique. As a result, both the targeted injection as well as the increased volume (resulting in wider spread) could contribute to the effect on the spastic muscle in the NMJ group. Both treatment arms experienced a high response rate to treatment, suggesting that a much larger study population is needed to be able to detect any difference, if present at all.. Different injection guidance techniques (electric stimulation and electromyography) were allowed, to reflect the situation in real-world clinical practice. In an attempt to increase recruitment, a protocol amendment was also made allowing use of ultrasound guidance techniques; however, only one patient was injected using this technique.
Given that the two main injection guidance techniques well balanced between groups, the specific technique used during the study was likely to have had only a limited impact on the overall results.
In summary, the current study provides further insights in the discussions of the effectiveness of BoNT injections targeted to NMJs. Since this strategy enables patients to be treated using fewer injections, the approach may minimize the potentially painful injection experience while having a similar effect on spasticity. Furthermore, the high number of responders with both injection techniques indeed confirms aboBoNT-A to be an effective treatment option for spasticity. Thus, any measures that could have an effect on implementation and/or compliance are important.
This study was conducted on flexors in the spastic arm, and the effect on other spastic muscles using NMJ targeted injections has yet to be substantiated. 
Data sharing statement
Trial data analyzed during the reported study are available to qualified researchers. Reasonable requests should be directed to the corresponding author. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 *We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials.
Enrollment
NMJ targeted Current clinical Practice
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
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